CANNABOTECH is developing innovative cannabinoid-based products that can be sold today under the regulation of Medical Cannabis in many countries worldwide.
One of the great challenges in the world of medical cannabis stems from the mismatch between products and the needs of the patients: cannabis consumers have to choose between hundreds of products through a long process of trial and error.
CANNABOTECH is set to develop the next generation of medical cannabis products: high quality products designated for use as medical cannabis with consistent potencies, and API concentrations that adhere to high standards concerning safety, consistency, and efficacy.
Building on the opportunities to create better medical cannabis products cannabotech aims to:
- Harness advanced R&D in collaboration with leading research institutes to create optimal compositions of cannabis APIs for three indications: Cancer support, chronic pain and inflammation
- Increase the bioavailability of cannabis APIs using simple delivery systems such as liposomes
- Create products standardized for defined APIs that may be THC, CBD and/or other cannabinoids including CBG, THCV, CBC
All our products will be based on cannabis oil extract combined with medical mushroom extracts. All stages of development and production will be done according to best practice guidelines including; cannabis cultivation under GAP guidelines, extraction and processing under GMP guidelines, and lipid-based formulation.